<DOC>
	<DOCNO>NCT01726894</DOCNO>
	<brief_summary>To determine adverse event genito-urinary side-effect profile focal therapy treat localise low intermediate risk prostate cancer use irreversible electroporation ( Nanoknifeâ„¢ ) .</brief_summary>
	<brief_title>Focal Therapy Localised Prostate Cancer Using Irreversible Electroporation</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Histologically proven prostate cancer , Gleason Score &lt; /=7 An anterior visible lesion mpMRI , accessible IRE treatment Transperineal prostate biopsy ( template mapping and/or limit target ) correlate clinically significant lesion area MRvisible lesion ( within 2 Barzell zone ) Absence clinically significant disease outside plan treatment zone , histopathology and/or mpMRI finding Stage radiologicalT1T2cN0M0 disease , determine local guideline Serum PSA &lt; /=15 ng/ml Life expectancy &gt; /= 10 year Signed informed consent patient An understanding English language sufficient understand write verbal information trial consent process Men previous radiation therapy Men androgen suppression/hormone treatment within previous 12 month prostate cancer Men evidence metastatic disease nodal disease outside prostate bone scan crosssectional image Men nonvisible tumour mpMRI Men inability tolerate transrectal ultrasound Men latex allergy Men undergone prior significant rectal surgery prevent insertion TRUS probe ( decide type surgery individual case ) Men previous IRE , HIFU , cryosurgery , thermal microwave therapy prostate . Men undergone Transurethral Resection Prostate ( TURP ) symptomatic low urinary tract symptom within 6 month . These patient may include within trial defer consent screen least 6 month follow TURP . Men fit major surgery assess Consultant Anaesthetist Men unable pelvic MRI scanning ( severe claustrophobia , permanent cardiac pacemaker , metallic implant etc likely contribute significant artefact image ) Presence metal implants/stents urethra Men renal impairment GFR &lt; 35ml/min ( unable tolerate Gadolinium dynamic contrast enhance MRI ) .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Focal Therapy</keyword>
</DOC>